Keen Kevzara Pricing Will Be Sanofi’s Best Hope After Speedy NICE Nod
A three-month turnaround from approval in Europe for Sanofi’s rheumatoid arthritis drug to recommendation in England is pretty quick. The firm will need to maintain keen pricing in a competitive field.
You may also be interested in...
Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
CEO Vas Narasimhan told Scrip how impressed he was by the resilience of the brand and while Cosentyx is holding its market share in dermatology, its rheumatology sales are continuing to fly high.